Novo Nordisk Valuation
| NONOF Stock | USD 106.83 0.24 0.23% |
At this time, the firm appears to be overvalued. Novo Nordisk AS secures a last-minute Real Value of $100.42 per share. The latest price of the firm is $106.83. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Profit Margin of 0.31 %, current valuation of 292.82 B, and Return On Equity of 0.72 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novo pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Novo Nordisk AS. Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Pink Sheet. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 106.83 | Real 100.42 | Hype 106.83 |
The real value of Novo Pink Sheet, also known as its intrinsic value, is the underlying worth of Novo Nordisk AS Company, which is reflected in its stock price. It is based on Novo Nordisk's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk Total Value Analysis
Novo Nordisk AS is now estimated to have takeover price of 292.82 B with market capitalization of 318.05 B, debt of 20.77 B, and cash on hands of 31.04 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novo Nordisk fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
292.82 B | 318.05 B | 20.77 B | 31.04 B |
Novo Nordisk Investor Information
About 39.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.94. Novo Nordisk AS last dividend was issued on the 12th of August 2022. The entity had 5:1 split on the 2nd of January 2014. Based on the analysis of Novo Nordisk's profitability, liquidity, and operating efficiency, Novo Nordisk AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Novo Nordisk Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novo Nordisk has an asset utilization ratio of 73.35 percent. This implies that the Company is making $0.73 for each dollar of assets. An increasing asset utilization means that Novo Nordisk AS is more efficient with each dollar of assets it utilizes for everyday operations.Novo Nordisk Ownership Allocation
Novo Nordisk AS maintains a total of 1.72 Billion outstanding shares. 30% of Novo Nordisk outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novo Nordisk Profitability Analysis
The company reported the revenue of 176.95 B. Net Income was 55.52 B with profit before overhead, payroll, taxes, and interest of 148.51 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novo Nordisk's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novo Nordisk and how it compares across the competition.
About Novo Nordisk Valuation
The pink sheet valuation mechanism determines Novo Nordisk's current worth on a weekly basis. Our valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novo Nordisk's related companies.Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on OTC Exchange in the United States.
8 Steps to conduct Novo Nordisk's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novo Nordisk's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novo Nordisk's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novo Nordisk's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novo Nordisk's revenue streams: Identify Novo Nordisk's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novo Nordisk's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novo Nordisk's growth potential: Evaluate Novo Nordisk's management, business model, and growth potential.
- Determine Novo Nordisk's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novo Nordisk's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Novo Nordisk Growth Indicators
Investing in growth stocks can be very risky. If the company such as Novo Nordisk does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.2 B | |
| Quarterly Earnings Growth Y O Y | 0.264 | |
| Forward Price Earnings | 29.7619 | |
| Retained Earnings | 80.6 B |
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |